The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis

To investigate treatment outcomes, hearing outcomes, and adverse effects of rituximab (RTX) for intractable otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV).

https://ift.tt/2kUuXXq